Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

ORIC Pharmaceuticals Expects Initial 1b Data For 3 Ongoing Trials In H1 2023

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate
byBenzinga Newsdesk
January 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Development candidate selected for PLK4 synthetic lethal breast cancer program

Cash and investments of $228 million expected to fund operating plan into first half of 2025

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Hydroponics Giant Announces $6M Share Repurchase Program, CEO Says Understanding ‘Where Every Nickel Goes’ Is Vital For Business Growth

By Jelena Martinovic
March 28, 12:20 PM
Beginning on April 1, the share repurchase program, will continue for up to one year, allowing for repurchases to be made in the open market. Darren Lampert, the company's co-founder and CEO, explained what the move means for GrowGen. "Today's announcement of our share repurchase program further underscores our conviction in the strength of our underlying business and our view that GrowGen shares remain undervalued," Lampert said. "This program acts as one pillar of our shareholder value creation strategy as we continue to evaluate all potential uses for our strong balance sheet, including reinvesting in our brands, strategic acquisitions, and stock repurchases to enhance long-term shareholder value."

GRWG